Compare RECT & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RECT | NRSN |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | Singapore | Israel |
| Employees | 111 | 16 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7M | 16.8M |
| IPO Year | N/A | N/A |
| Metric | RECT | NRSN |
|---|---|---|
| Price | $1.24 | $0.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 8.8K | ★ 185.6K |
| Earning Date | 03-20-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | $12.74 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.96 | $0.39 |
| 52 Week High | $4.98 | $1.33 |
| Indicator | RECT | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 33.34 |
| Support Level | $1.06 | N/A |
| Resistance Level | $1.40 | $0.74 |
| Average True Range (ATR) | 0.17 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 26.15 | 33.65 |
Rectitude Holdings Ltd is principally involved in the provision of safety equipment, encompassing essential items such as personal protective clothing, hand gloves, safety footwear, and personal fall arrest systems (a system used to arrest an employee in a fall from a walking-working surface, usually consisting of a body harness, anchorage, and connector), portable fire extinguishers and traffic products such as rubber speed humps, wheel stops and wheel chocks. Additionally the company has added auxiliary products such as industrial hardware tools and electrical hardware required for construction sites.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.